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Summary: Conjugates of the catechol compounds, L-dihydroxyphenylalanine (L-DOPA), dopamine and dihydroxy-
phenylacetic acid in human urine were analysed using the isocratic ion-pair reversed-phase HPLC method with
electrochemical detection. Acid hydrolysis, using 4 mol/1 HC1 for 60 min, was more effective than treatment with
sulphatase for the generation of free catechols. Free (non-conjugated) catechols already present, as well as those
produced by either of the hydrolysis procedures, were adsorbed onto aluminium oxide and extracted in acid solution.
The repeatability of the technique for within and between-batch urine analysis was less than 2% and 8%, respec-
tively.
Free urinary dopamine (and dihydroxyphenylacetic acid) concentrations were much higher in the urine of patients
treated with L-DOPA for Parkinson's disease than in healthy volunteers. At high dopamine (and dihydroxyphenyl-
acetic acid) levels the conjugation capacity was apparently exceeded, since the overall percent conjugation of L-
DOPA, dopamine and dihydroxyphenylacetic acid was decreased "concentration dependency" when the concentra-
tions of free catechols were increased. Both in the control group and L-DOPA-treated groups, enzymatic hydrolysis
was much less effective than acid hydrolysis in generating free catechols. This indicated that there were other, non-
sulphated conjugates in the urine, accounting for between 66 and 100% of total conjugates.
Introduction
Conjugation reactions play a significant role in the me-
tabolism of catecholamines and their oxidation products
(1). Different analytical techniques have been used for
determinations of catecholamines. HPLC methods with
electrochemical or fluorescence detection have been de-
scribed (2). A gas-chromatographic/mass-spectrometric
method has also been reported (3). Liquid chromatogra-
phy is the method of choice for the assay of catechol-
amines and metabolites, having the advantages of ana-
lytical sensitivity and selectivity. To measure the total
concentrations of the catechols in urine, it is necessary
to hydrolyse the samples before the HPLC analysis.
Both enzymatic (4) and acid hydrolysis methods (5)
have been used, but there is no consensus about how
these methods should be optimally applied.
We found accidentally that the percentage release of
dopamine and its metabolite, dihydroxyphenylacetic
acid, from urine by hydrolysis, differed greatly for
patients on L-dihydroxyphenylalanine (L-DOPA) ther-
apy and healthy subjects. It seemed that hydrolysis
was inhibited either by the high catechol levels result-
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ing from the L-DOPA therapy, or by dopa decarboxyl-
ase inhibitors.
These preliminary findings prompted us to study in de-
tail some of the factors affecting enzymatic and acid
hydrolysis. Free L-DOPA, dopamine and dihydroxyphe-
nylacetic acid in urine, both before and after various hy-
drolysis procedures, were adsorbed onto aluminium ox-
ide, then extracted into acidic solution. The concentra-
tions of catechols were determined by ion-pair reversed-
phase chromatography and detected using an electro-
chemical detector. After the initial validation of the hy-
drolysis and analysis, the overall method was applied to
clinical urine samples to compare the conjugation pro-
file of catechols in the urine of healthy volunteers (very
low dopamine levels) and patients treated with L-DOPA
and dopa decarboxylase inhibitors (moderate or high do-
pamine concentrations).
Materials and Methods
Reagents
Ultrapure reagent-grade water was obtained with a Milli-Q sys-
tem (Millipore Corporation, Milford, MA, USA). The solvents
for chromatography were HPLC-grade (Rathburn, Walkerburn,
UK) and the chemicals analytical grade. Aluminium oxide
(A12O3), citric acid, disodium EDTA dihydrate, hydrogen chlo-
ride (HC1), perchloric acid, phosphoric acid, sodium acetate,
sodium chloride, sodium dihydrogen phosphate and sulphuric
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acid were purchased from E. Merck (Darmstadt, Germany). Do- amine, heptane sulphonic acid, tris(hydroxymethyl)aminomethane
pamine, dihydroxyphenylacetic acid, L-DOPA, dihydroxybenzyl- hydrochloride and arylsulphatase (aryl-sulphate sulphohydrolase;
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Fig. 1 Chromatograms derived from urine samples of the control (d) after enzymatic hydrolysis (18.4 U sulphatase in 400 μΐ reaction
subject. Urine sample: mixture for 60 min at 37 °C).
(a) before acid hydrolysis, Peaks: 2 = dihydroxybenzylamine, 3 = dopamine, 4 = dihydroxy-
(b) after acid hydrolysis (4 mol/1 HC1 for 60 min at 95 °C), phenylacetic acid, 5 = unknown extra peak.
(c) before enzymatic hydrolysis,
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Fig. 2 Chromatograms derived from the urine samples of the pa-
tient treated with L-DOPA. Urine sample:
(a) before acid hydrolysis,
(b) after acid hydrolysis (4 mol/1 HC1 for 60 min at 95 °C).
(c) before enzymatic hydrolysis,
(d) after enzymatic hydrolysis (18.4 U sulphatase in 400 μΐ reaction
mixture for 60 min at 37 °C).
Peaks: 1 = Z,-DOPA, 2 = dihydroxybenzylamine, 3 = dopamine,
4 = dihydroxyphenylacetic acid, 5 = unknown extra peak.
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Tab. 1 Intra- and inter-assay precision of analysis for dopamine,
dihydroxyphenylacetic acid and L-DOPA in urine samples at two
concentration levels (n = 4).
L-DOPA
Dopamine
Dihydroxyphenyl-
acetic acid
Mean
(mg/1)
56.9
25.1
56.5
17.7
38.0
9.2
Intra-
assay CV
(%)
1.6
0.3
1.7
2.0
1.2
1.0
Inter-
assay CV
(%)
7.7
4.6
6.6
6.7
8.4
3.5
EC 3.1.6.1; type H-l from Helix pomatia) were purchased from
Sigma (St. Louis, MO, USA).
Standard solutions
Stock solutions (1 g/1) of L-DOPA, dopamine and dihydroxy-
phenylacetic acid were prepared by dissolving the compounds in
0.4 mol/1 HC1O4 containing 1 g/1 Na2S2O5 and 150 mg/1 EDTA.
Working standard solutions, containing 2000 μ§/1 of each sub-
stance and internal standard dihydroxybenzylamine (125 μg/l),
were prepared by diluting the stock solutions in the 0.4 mol/1
HC1O4 solution. The stock solutions were stored at + 4 °C and
used within 4 months. The working standard dilutions were pre-
pared daily.
Liquid chromatography
The HPLC system consisted of an isocratic Waters Model 6000A
pump with dual SSI suppressors in series, a Waters 712 Wisp auto-
injector with cooler (Waters Association, Milford, MA, USA) and
a Hewlett-Packard 3396 series II recording integrator (Palo Alto,
CA, USA). An analytical cell 5011 of ESA Coulochem Model
5100A coulometric detector (ESA, Inc, USA) set at +0.10 V/-
0.30 V with conditioning cell 5021 set + 0.50 V was used. Spherex
5 CIS column (5 μπι, 125 X 4.6 mm I.D., Phenomex, Torrance,
CA, USA) with Separon SGX C18 precolumn was used for analyti-
cal separations.
The isocratic mobile phase contained 0.1 mol/1 Na2HPO4, 0.15
mmol/1 EDTA, 20 mmol/1 citric acid, 1.0 mmol/1 heptane sulphonic
acid and methanol, volume fraction 0.1, pH 3.0. This filtered eluent
was degassed before use. The flow rate was 0.7 ml/min. The indivi-
dual compounds were screened by comparing their absolute reten-
tion times with those of the standard compounds.
Sample preparation
The urine samples from 7 patients with Parkinson's disease were
collected during 2—4 h after the first morning dose (6). Similarly,
the urine samples of 5 healthy control subjects without drug ther-
apy were collected. The specimens were taken into plastic bottles
containing 2.5 ml of 6 mol/1 HC1 as a preservative and stored at
-20 °C until assay.
Free catechol compounds from urine were selectively extracted
onto A12O3 before quantification based on the modification of a
previous method (7). One millilitre of diluted urine sample (1:2
or 1 : 20 in healthy controls and 1 : 20 or 1 : 200 in patients on L-
DOPA therapy; see below) was mixed with 600 μΐ of 1.5 mol/1
Tris-HCl buffer pH 8.6 and placed on 50 mg of A12O3, after which
10 μΐ of internal standard containing 125 ng of dihydroxybenzyl-
amine was added. The pH of the sample was kept between 8.5 and
8.7. The samples were mixed in a shaker for 10 min and centri-
fuged (10 min at 2000 g at + 4 °C) after which the supernatants
were aspirated. The A12O3 was washed twice with 1.5 ml of water.
Ζ,-DOPA, dopamine and dihydroxyphenylacetic acid were ex-
tracted by shaking the samples for 10 min with 1 ml of 0.4 mol/1
HC1O4 containing 1 g/1 Na2S2O5 and 150 mg/1 EDTA. After centri-
fugation the supernatant was filtered (Acrodisc LC filter, 0.45 urn,
Gelman Sciences, Ann Arbor, MI, USA) into a HPLC tube and
Tab. 2 Enzymatic hydrolysis of urine samples taken from healthy control subjects and L-DOPA treated
patients with sulphatase for 60 min at 37 °C.
Control subjects L-DOPA-treated patients
L-DOPA
Control
9.2 U sulphatase
18.4 U sulphatase
Concentration Efficacy of
(mg/l)a hydrolysis"
2
5
2
Concentration
(mg/l)a
28.6
28.2
27.4 ± 0.9
28.2
Efficacy of
hydrolysis13
-3.2
-0.5
Dopamine
Control
9.2 U sulphatase
18.4 U sulphatase
Dihydroxyphenylacetic acid
0.34 ± 0.01
0.47 ± 0.02
0.52 ± 0.01
40
55
a
 Mean ± SD
b After hydrolysis — Before hydrolysis
Before hydrolysis
X 100
28.3
12.4
12.2
19.8 ± 0.4
22.8
22.5
61
84
Control
9.2 U sulphatase
18.4 U sulphatase
4
8
4
1.39 ± 0.03
1.52 ± 0.04
1.60 ± 0.02
9
15
2
5
2
28.7
28.4
40.8 ± 0.7
40.3
39.8
43
40
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stored at —80 °C for chromatography. A 20 μΐ aliquot of sample
was injected into HPLC system.
Enzymatic hydrolysis of urine samples
To reveal the presence of sulphate conjugates of catechol com-
pounds, aliquots (100 μΐ) of diluted urine (1 : 2 or 1 : 20 using 0.02
mol/1 HC1 in the samples of healthy controls and patients on L-
DOPA therapy, respectively) were buffered with 200 μΐ of 0.2 mol/1
acetate buffer, pH 5, and treated with arylsulphatase (9.2 or 18.4
units) dissolved in 100 μΐ of ice cold 2 g/1 sodium chloride solution.
The incubation time was l h at + 37 °C. The reaction was stopped
placing in an ice bath. The hydrolysed sample was adsorbed onto
A12O3 and extracted as above.
Acid hydrolysis of urine samples
To compare the hydrolysis of conjugated catecholamines with dif-
ferent acids, 150 μΐ of either 4 mol/1 HC1,4 mol/1 HC1O4 or 4 mol/1
H2SO4 were added to 1 ml of a diluted urine sample (1 :20 or
1 : 200 with the solution containing 1 g/1 of Na2S2O5 and 150 mg/1
EDTA in samples of healthy controls and patients on L-DOPA ther-
apy, respectively), and incubated for 60 min. To detect the effect
of time on hydrolysis with 4 mol/1 HC1, various incubation times
(30, 60, 90 and 120 min) were used. This mixture was heated for
l h at + 95 °C in an oven and then cooled on ice. Finally, it was
adsorbed onto A12O2 and desorbed into acidic solution as above.
Calibration and calculation
For each HPLC run the method was calibrated with 5 concentra-
tions (10—400 μg/l) of calibration samples of Ζ,-DOPA, dopamine
and dihydroxyphenylacetic acid, containing internal standard (125
μg/l of dihydroxybenzylamine). Peak-height ratios of each com-
pound to internal standard, obtained from actual standards, were
plotted against the concentrations of each substance to generate a
linear least-squares regression line with QuattroPro software (Bor-
land International, Scotts Valley, CA, USA). The reliability was
assessed by calculating the intra-assay and inter-assay coefficient
of variation (CV).
Results
Liquid chromatography of L-DOPA, dopamine
and dihydroxyphenylacetic acid
Ζ,-DOPA, dopamine and dihydroxyphenylacetic acid
were detected simultaneously in urine samples by
isocratic ion-pair reversed-phase HPLC (figs. 1 and 2).
Before the Chromatographie separation, it was necessary
to perform an alumina absorption to remove non-cate-
chol compounds and impurities in matrices.
Because electrochemical detection was used, the calibra-
tion had to be performed separately for each analyte.
The electrical responses (heights) were linear with corre-
lation coefficients of more than 0.999 for the standard
compounds from 10 to 400 μg/l. The detection limit of
the assay (peak height three times the baseline noise)
was 10 pg for dopamine and Ζ,-DOPA and 15 pg for di-
hydroxyphenylacetic acid.
The assay of free compounds indicates the repeatability
of the technique for both within and between-batch urine
analysis at the two concentration levels studied (tab. 1).
The intra-assay CVs varied between 0.3% and 2%,
whereas inter-assay CVs were between 3.5% and 8.4%.
In the acid hydrolysis using 4 mol/1 HC1, analytical re-
coveries of 200 μg/l were 82.3%, 82.2% and 88.2% with
CV% 1.5, 1.8 and 2.0 for Ζ,-DOPA, dopamine and dihy-
droxyphenylacetic acid standards, respectively. In the
enzymatic hydrolysis, the recoveries of 200 μg/l of the
three compounds were 88.5%, 89.0% and 92.6% with
CV% of 9.7, 6.8 and 9.4, respectively. After spiking
urine samples with 100 μg/l of each standard, the recov-
eries of Ζ,-DOPA, dopamine and dihydroxyphenylacetic
acid were 82.6 ± 6.7% (mean ± CV%), 85.9 ± 6.7%
and 91.0 ± 7.4%, respectively.
Enzymatic hydrolysis of urine samples
The effect of two arylsulphatase concentrations (9.2 and
18.4 U in two samples after 60 min incubation (30 min
suggested by the supplier) is shown in table 2. Incubation
times exceeding 60 min did not increase but rather de-
creased the amount of deconjugated compounds (data not
shown). The use of a sulphatase preparation (type-1) from
Helix pomatia did not interfere with the chromatography.
The enzymatic hydrolysis was found to be strongly inhib-
ited in the presence of 1 mmol/1 of Na2S2O5. Sulphatase
was also weakly active when the hydrolysis was per-
formed in phosphate buffer (data not shown). It was not
feasible to run the internal standard through the hydrolysis
process since it was significantly decomposed during in-
cubation. Therefore the internal standard was added at the
alumina absorption stage, where its recovery was satisfac-
tory (89.2%).
Acid hydrolysis of urine samples
The effects of different acids on the hydrolysis are
shown in table 3. The differences were minor during 60
min incubation. The use of 4 mol/1 HC1 and the 60 min
incubation at + 95 °C was adequate for the hydrolysis
Tab. 3 Effect of different acids on hydrolysis of dopamine and
dihydroxyphenylacetic acid conjugates in urine of healthy volun-
teers during 60 min incubation at + 95 °C.
Dopamine
Control
4 mol/1 HC1C
4 mol/1 HC1O4C
4 mol/1 H2SO4a
Dihydroxyphenylacetic acid
Control
4 mol/1 HC1C
4 mol/1 HC1O4C
4 mol/1 H2SO4C
n
4
8
6
6
4
8
6
6
Concentration
(mg/l)a
0.30 ± 0.02
1.10 ±0.04
1.12 ±0.02
1.14 ±0.04
0.96 ± 0.04
1.93 ±0.05
1.87 + 0.03
1.79 ±0.04
Efficacy of
hydrolysis15
265
271
279
101
94
86
a
 Mean ± SD
b After hydrolysis — Before hydrolysis X 100
Before hydrolysis
Final concentration in hydrolysis mixture 0.52 mol/1
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Fig. 3 Effect of hydrolysis time on the liberation of free catechols
(I-DOPA, dopamine, dihydroxyphenylacetic acid) as a function of
time using 4 mol/1 HC1 at + 95 °C. Studies were done using urine
samples from both healthy controls (n = 4) and from patients re-
ceiving I-DOPA (n = 4). Mean ± SD.
of conjugated Ζ,-DOPA, dopamine and dihydroxy-
phenylacetic acid. The effect of time (30—120 min) on
the hydrolysis of urine samples is shown in figure 3. The
hydrolysis was not complete after the 30 min incubation.
There was no difference between 60 min and 90 min
incubations. Ζ,-DOPA and dopamine liberation was
slightly increased during prolonged incubation but dihy-
droxyphenylacetic acid levels were rather decreased.
However, the compounds did not decompose during acid
hydrolysis (fig. 3).
Comparison of healthy volunteers and
patients with Parkinson's disease
An initial comparison was made during the validation
process (tab. 2 and fig. 3). Our studies showed that enzy-
matic hydrolysis was equally effective for urine samples
from the healthy controls and from the patients on L-
DOPA therapy. However, the percentage hydrolysis by
acid was much smaller in the latter than in the former
urine samples.
In the more precise comparison, the urinary dopamine
concentration of 5 control persons varied from 0.23 to
0.47 (0.30 ±0.10 mg/1; mean ± SD), and dihydroxy-
phenylacetic acid concentrations from 1.1 to 5.1 (1.21
± 0.66 mg/1; mean ± SD). In 7 Ζ,-DOPA treated patients
the concentrations of dopamine were 50—200-fold and
those of dihydroxyphenylacetic acid 30—40-fold greater
than the control values. Generally, the variations be-
tween subjects was several-fold.
In healthy volunteers, with very low free dopamine
levels, the quantity of dopamine was increased nearly 9-
fold by acid hydrolysis, whereas that of dihydroxyphe-
nylacetic acid was increased only 1.5-fold. Much smaller
quantities of catechols were released by enzymatic hy-
drolysis than by acid hydrolysis, indicating that other
conjugates were present in urine, in addition to sul-
phates. The amounts of these other conjugates showed
wide variations, but they usually exceeded those of the
sulphate conjugates (tab. 4; fig. 4).
We divided the 7 Parkinsonian patients into two groups
based on the free dopamine concentrations before hy-
drolysis (moderate dopamine, < 20 mg/1, and high do-
pamine group, > 50 mg/1; tab. 4). In the moderate dopa-
mine group, the proportion of dopamine after acid hy-
drolysis was increased by 64% during hydrolysis. Cor-
respondingly, in the high dopamine group the proportion
of dopamine was increased only by 30%. After acid hy-
drolysis the proportion of dihydroxyphenylacetic acid
was increased by 48% in the moderate dopamine group,
Tab. 4 Effect of acid hydrolysis (4 mol/1 HCl for 60 min at
+ 95 °C) and sulphatase treatment (18.4 U in 400 μΐ reaction mix-
ture for 60 min at + 37 °C) on the liberation of free catechols from
the urine of control subjects (low dopamine) and patients treated
with Ζ,-DOPA (moderate and high dopamine concentrations).
Control subjects (n = 5)
Dopamine
Dihydroxyphenylacetic acid
Concentration of
catecholamines
released by acid
(= total conjugates)
mg/1
(Mean ± SD)
2.6 ± 3.0
1.6 ± 1.0
Concentration of
catecholamines
released by sulphatase
mg/1
(Mean ± SD)
0.45 ± 0.49
0.45 ± 0.30
Other
conjugates
mg/1
(Mean ± SD)
2.2 ± 2.5
1.1 ±0.7
Proportion of
other conjugates
from total
conjugates
%
82.0 ± 7.1
71.0 ± 6.5
L-DOPA treated subjects
Moderate dopamine (< 20 mg/1) (n = 3)
Ζ,-DOPA 6.3 ± 2.0
Dopamine 10.7 ± 5.6
Dihydroxyphenylacetic acid 16.7 ± 18.7
High dopamine (> 50 mg/1) (n = 4)
L-DOPA 8.8 ± 3.0
Dopamine 19.7 ± 9.7
Dihydroxyphenylacetic acid 4.9 ± 2.2
1.1 ± 2.0
4.2 ± 5.0
10.4 ± 13.8
0.0
4.3 ± 3.8
0.4 ± 0.6
5.2 ± 1.1
6.5 ± 1.3
6.3 ± 4.9
8.8 ± 3.0
15.4 ± 6.4
4.6 ± 1.9
87.7 ± 22.5
70.9 ± 27.0
66.3 ± 37.6
100.0
81.6 ± 16.2
94.5 ± 8.6
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and only by 10% in the high dopamine group (fig. 4).
Only minor quantities of L-DOPA conjugates were pre-
sent, and they were not hydrolysed at all by sulphatase.
The overall percentage conjugation of L-DOPA, dopa-
mine and dihydroxyphenylacetic acid showed a concen-
tration-dependent decrease, as the concentrations of the
free compounds increased (fig. 4).
As in the control group, much smaller quantities of cate-
chols were released by enzymatic hydrolysis, both in the
low and the moderate dopamine groups, than by acid
hydrolysis, indicating that there were other conjugates
in the urine. These other conjugates accounted for 66 to
100% of the total conjugates (tab. 4; fig. 4).
Discussion
Since conjugation reactions play a significant role in the
metabolism of catecholamines (1, 8) it is important to be
able to quantify them. We have now compared procedures
used to quantify free and conjugated forms of the catechol
compounds, L-DOPA, dopamine and dihydroxyphenyl-
acetic acid in urine after acid and enzymatic hydrolysis.
Basal catechol levels and the quantities of conjugates dis-
play marked variations between individuals. Our conclu-
sion is that the use of 4 mol/1 HC1 for 60 min at + 95 °C
gives satisfactory results. The degree of hydrolysis is only
slightly increased by 120 min hydrolysis. Other acids pro-
duce similar results after 60 min incubation for the hydrol-
ysis of the dopamine conjugates, but show different effi-
ciencies of hydrolysis for conjugates of dihydroxyphenyl-
acetic acid. The studies showed that a maximum incuba-
tion time of one hour was needed for optimum hydrolysis
of the analytes without decomposition. We found that at
least 0.52 mol/1 of HC1O4 was needed for adequate hy-
drolysis in 60 min, which differs from the conditions re-
ported by Elchisak et al. (9). Incubation for a further hour
did not increase the hydrolysis.
The enzymatic procedure using sulphatase gives a less
complete hydrolysis of conjugated catecholamines. This
is partially due to the fact that other conjugates are pre-
sent, which are not hydrolysed by sulphatase. In fact,
non-sulphate conjugates seem to be more abundant than
sulphate conjugates. Enzyme preparations are not easy
to use; they are sometimes sticky and quite expensive.
Therefore acid hydrolysis is generally preferred from a
practical point of view too.
Fig. 4 Efficacy of enzymatic (18.4 U in 400 μΐ reaction mixture
for 60 min at + 37 °C) and acid hydrolysis (4 mol/1 HC1 for 60 min
at + 95 °C) in healthy volunteers (low dopamine in urine) and in
patients receiving L-DOPA (divided into moderate and high dopa-
mine groups), where a = L-DOPA, b = dopamine and c = dihy-
droxyphenylacetic acid.
Mean ± SD. The efficacy is expressed as the percentage increase
of the free catechol from the initial free concentration.
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For determination of urinary catecholamines the samples
must be collected in acid to avoid spontaneous oxidation
(10). However, pH-values less than I can decrease the
recoveries of catecholamine (11). We collected the urine
specimens in 6 mol/1 HC1, and pH remained between 1.5
and 2.0. In many laboratories antioxidants, e. g., ascorbic
acid, Na2S2O5 or dithiothreitol (8, 9) are added to pre-
vent oxidation during the hydrolysis procedure. We
found, however, that the enzyme hydrolysis was inhib-
ited by 1.3 mmol/1 of Na2S2O5 in the incubation solu-
tion. It has been reported that the hydrolysis of nor-
adrenaline was considerably inhibited by adding ascor-
bic acid (0.5 — 10 mmol/1) and slightly inhibited by dithio-
threitol (1 — 10 mmol/1) in plasma (12). On the other
hand, the hydrolysis of dopamine was not inhibited by
ascorbic acid or dithiothreitol (12). In our hands
Na2S2O5 did not affect the acid hydrolysis at all.
Dihydroxybenzylamine is frequently used as an in-
ternal standard in catecholamine analyses. Its recovery
is the same as that of endogenous catecholamines in
human and rodent plasma, while the recovery in dog,
horse and goat plasma is rather less than that in hu-
man plasma (13). In our hands, the recovery of dihy-
droxybenzylamine decreased during enzymatic hydrol-
ysis, although the recoveries of catechol compounds
did not. Therefore we added dihydroxybenzylamine
only after the enzymatic or acid hydrolysis, and before
the alumina procedure.
During validation of our method we accidentally found
that a large unknown peak appeared during the acid hy-
drolysis. This seriously marked the detection of dihy-
droxyphenylacetic acid, since it was extracted in both
the alumina and solid phase procedures. Its retention
time was insensitive to pH changes, but when heptane
sulphonic acid was used instead of octane sulphonic acid
in the mobile phase, we finally succeeded in separating
it from the dihydroxyphenylacetic acid peak (fig. 1 and
2). This exemplifies the practical interference problem
when working with a biological matrix.
The initial dopamine (and dihydroxyphenylacetic acid)
levels seemed to dictate the degree of hydrolysis.
These findings are interpreted as follows. At high uri-
nary dopamine (and dihydroxyphenylacetic acid)
levels, such as those seen in the L-DOPA treated
patients, the capacity of conjugation is saturated and
the free dopamine (and dihydroxyphenylacetic acid)
concentrations are much higher than those in the heal-
thy volunteers. Hydrolysis releases even more dopa-
mine (and dihydroxyphenylacetic acid) from urine of
the patients whose conjugation capacity almost or to-
tally exhausted, than from the urine of the healthy
controls whose still have a relatively high conjugation
capacity. The percentage hydrolysis is decreased in the
samples from L-DOPA-treated patients, owing to their
much higher catechol concentrations.
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